Hepatitis C Virus-related Glomerulonephritis with Acute Kidney Injury Requiring Hemodialysis That Improved with Virus Removal and Eradication Using Double-filtration Plasmapheresis Without Interferon

Overview

Journal CEN Case Rep

Specialty Nephrology

Date 2017 May 17

PMID 28509265

Citations 1

Authors

Akiko Morisue

Kosuke Fukuoka

Ruiko Goto

Kosuke Ota

Haruhiro Yamashita

Yoko Shinno

Ichiro Yamadori

Affiliations

Soon will be listed here.

Abstract

A 66-year-old, hepatitis C virus (HCV)-positive woman was admitted to our hospital with oliguria, systemic edema, and rapid deterioration of renal function. Laboratory examination showed increased serum creatinine and decreased serum albumin levels, complement activity, and cryoglobulin positivity. The HCV RNA genotype was found to be 1b, and the viral load was high. Kidney biopsy examination showed type I membranoproliferative glomerulonephritis with capillary deposition of IgM and C3, indicating HCV-related glomerulonephritis. After hospitalization, hemodialysis was immediately required because of uremia and oliguria. Her renal function did not improve despite corticosteroid therapy. To treat the increasing HCV load, virus removal and eradication by double-filtration plasmapheresis therapy without interferon was performed, since the patient was allergic to interferon therapy. This treatment improved renal function and allowed the withdrawal from hemodialysis. This report presents a case of successful VRAD without interferon therapy in a patient with HCV-related glomerulonephritis and acute kidney injury that required hemodialysis.

Citing Articles

Mechanistic Aspects and Therapeutic Potential of Quercetin against COVID-19-Associated Acute Kidney Injury.

Leite Diniz L, de Santana Souza M, Duarte A, de Sousa D Molecules. 2020; 25(23).

PMID: 33297540 PMC: 7730372. DOI: 10.3390/molecules25235772.

References

Hayashi J, Ohmiya M, Kishihara Y, Tani Y, Kinukawa N, Ikematsu H . A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol. 1994; 89(12):2151-6. View

Meyers C, Seeff L, Stehman-Breen C, Hoofnagle J . Hepatitis C and renal disease: an update. Am J Kidney Dis. 2003; 42(4):631-57. DOI: 10.1016/s0272-6386(03)00828-x. View

Yamashita T, Arai K, Sakai A, Mizukoshi E, Sakai Y, Kagaya T . Virological effects and safety of combined double filtration plasmapheresis (DFPP) and interferon therapy in patients with chronic hepatitis C: A preliminary study. Hepatol Res. 2006; 36(3):167-75. DOI: 10.1016/j.hepres.2006.07.013. View

Komatsuda A, Imai H, Wakui H, Hamai K, Ohtani H, Kodama T . Clinicopathological analysis and therapy in hepatitis C virus-associated nephropathy. Intern Med. 1996; 35(7):529-33. DOI: 10.2169/internalmedicine.35.529. View

Sanai T, Watanabe I, Hirano T, Nakayama M, Sakai H, Uesugi N . Successful steroid treatment in a patient with membranoproliferative glomerulonephritis associated with hepatitis C virus. Int Urol Nephrol. 2008; 41(1):179-83. DOI: 10.1007/s11255-007-9322-7. View

Kamar N, Rostaing L, Alric L . Treatment of hepatitis C-virus-related glomerulonephritis. Kidney Int. 2006; 69(3):436-9. DOI: 10.1038/sj.ki.5000142. View

Fujiwara K, Kaneko S, Kakumu S, Sata M, Hige S, Tomita E . Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load. Hepatol Res. 2007; 37(9):701-10. DOI: 10.1111/j.1872-034X.2007.00117.x. View

. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008; (109):S1-99. DOI: 10.1038/ki.2008.81. View

Morales J, Kamar N, Rostaing L . Hepatitis C and renal disease: epidemiology, diagnosis, pathogenesis and therapy. Contrib Nephrol. 2012; 176:10-23. DOI: 10.1159/000333772. View

10.

Namba T, Shiba R, Yamamoto T, Hirai Y, Moriwaki T, Matsuda J . Successful treatment of HCV-related cryoglobulinemic glomerulonephritis with double-filtration plasmapheresis and interferon combination therapy. Clin Exp Nephrol. 2010; 14(4):372-6. DOI: 10.1007/s10157-010-0282-3. View

11.

Dammacco F, Sansonno D, Han J, Shyamala V, Cornacchiulo V, Iacobelli A . Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood. 1994; 84(10):3336-43. View

12.

Sandri A, Elewa U, Poterucha J, Fervenza F . Treatment of hepatitis C-mediated glomerular disease. Nephron Clin Pract. 2011; 119(2):c121-9. DOI: 10.1159/000325220. View

13.

Johnson R, Gretch D, Yamabe H, Hart J, Bacchi C, Hartwell P . Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med. 1993; 328(7):465-70. DOI: 10.1056/NEJM199302183280703. View

14.

Fabrizi F, Aghemo A, Messa P . Hepatitis C treatment in patients with kidney disease. Kidney Int. 2013; 84(5):874-9. DOI: 10.1038/ki.2013.264. View

15.

Layden T, Lam N, Wiley T . Hepatitis C viral dynamics. Clin Liver Dis. 2001; 3(4):793-810. DOI: 10.1016/s1089-3261(05)70239-7. View

16.

Perico N, Cattaneo D, Bikbov B, Remuzzi G . Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol. 2009; 4(1):207-20. DOI: 10.2215/CJN.03710708. View

17.

Ahmed M, Wong C, Shawki H, Kapoor N, Pandya B . Rapidly deteriorating renal function with membranoproliferative glomerulonephritis Type 1 associated with hepatitis C treated successfully with steroids and antiviral therapy: a case report and review of literature. Clin Nephrol. 2008; 69(4):298-301. DOI: 10.5414/cnp69298. View